Skip to main content

Free Content High frequency of multidrug-resistant Mycobacterium tuberculosis isolates in Georgetown, Guyana

Download Article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library



Emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis isolates constitutes a threat to public health worldwide. This study aimed at acquiring first epidemiological data for Guyana. Thirty-six M. tuberculosis isolates from patients of the Georgetown Chest Clinic were subjected to susceptibility testing on solid agar and in broth media. Resistance to at least one first-line drug was observed in 8 (22.2%, 95% confidence interval 8.3–36.1%) and simultaneous resistance to rifampicin and isoniazid (MDR) in 4 (11.1%, 95% confidence interval 0.6–21.6%) of the 36 isolates. The risk of infection with resistant isolates was significantly related to earlier antituberculosis therapy (P = 0.040). These data indicate a high proportion of resistant M. tuberculosis isolates in Guyana and call for the implementation of control strategies based on an improved laboratory diagnosis of TB.

Keywords: Guyana; multidrug resistance; tuberculosis

Document Type: Research Article


Affiliations: 1: Department of Medical Microbiology and Immunology of Infection, Charité– University Medicine Berlin, Berlin, Germany 2: Faculty of Health Sciences, School of Medicine, University of Guyana, Georgetown, Guyana 3: Department of Biostatistics and Clinical Epidemiology, Charité– University Medicine Berlin, Berlin, Germany 4: Institute for Microbiology, Immunology, and Laboratory Medicine, Hospital Zehlendorf-Heckeshorn, Berlin, Germany 5: Ministry of Health Guyana, Georgetown, Guyana

Publication date: December 1, 2005


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more